Raza Shahzad, Kale Gautam, Kim Daniel, Akbar Syed A, Holm Lisa, Naidzionak Ulad, Hossain Akm M, Dong Xiang, Doll Donald C, Freter Carl E, Hopkins Tamara
Division of Hematology & Oncology, Ellis Fischel Cancer Center, University of Missouri Health Care, Columbia, MO, USA
Division of Hematology & Oncology, Ellis Fischel Cancer Center, University of Missouri Health Care, Columbia, MO, USA.
Clin Appl Thromb Hemost. 2016 Mar;22(2):161-5. doi: 10.1177/1076029614543139. Epub 2014 Jul 9.
Total hip replacement (THR) and total knee arthroplasty (TKA) carry a high risk of postoperative venous thromboembolism (VTE); therefore, anticoagulation prophylaxis is recommended in these patients. Unfortunately, there are no guidelines about VTE prophylaxis in patients with hemophilia who underwent these high-risk surgeries. To determine whether these patients have high risk of VTE, we conducted a retrospective study on patients with hemophilia who underwent elective THR/TKA at our institute from 2004 to 2012. Postoperatively, we collected information on duration and method of factor VIII/IX infusion, VTE-prophylaxis, and complications. There were 23 patients with hemophilia, 18 (78%) with hemophilia A and 5 (22%) with hemophilia B, who underwent high-risk surgeries (39% THR and 61% TKA). The VTE prophylaxis included sequential compression device, 12 (52%), and prophylactic enoxaparin, 1 (4%). Ten (43%) patients did not receive VTE prophylaxis. At 1-year follow-up, we did not find any evidence of clinical VTE in our patients. Better risk stratification is needed to identify patients who would benefit from pharmacological prophylaxis.
全髋关节置换术(THR)和全膝关节置换术(TKA)术后发生静脉血栓栓塞症(VTE)的风险很高;因此,建议对这些患者进行抗凝预防。不幸的是,对于接受这些高风险手术的血友病患者,尚无VTE预防的指南。为了确定这些患者是否具有VTE高风险,我们对2004年至2012年在我院接受择期THR/TKA的血友病患者进行了一项回顾性研究。术后,我们收集了关于VIII/IX因子输注的持续时间和方法、VTE预防及并发症的信息。共有23例血友病患者接受了高风险手术(39%为THR,61%为TKA),其中18例(78%)为A型血友病,5例(22%)为B型血友病。VTE预防措施包括序贯加压装置,共12例(52%),预防性使用依诺肝素1例(4%)。10例(43%)患者未接受VTE预防。在1年的随访中,我们未在患者中发现任何临床VTE的证据。需要更好的风险分层来识别将从药物预防中获益的患者。